[
  {"id":"B02-20160301-001","en":"ANDS (Abbreviated New Drug Submission)","fr":"PADN (Présentation abrégée de drogue nouvelle)"},
  {"id":"B02-20160301-031","en":"EU NDS (Extraordinary Use New Drug Submission)","fr":"PDN-UE (Présentation de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20160301-032","en":"EUSNDS (Extraordinary Use Supplement to a New Drug Submission)","fr":"SPDN-UE (Supplément à une présentation de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20160301-038","en":"Level 3 - Notice of Change","fr":"Niveau 3 -Déclaration de changements"},
  {"id":"B02-20160301-046","en":"MPNC (Pre-NC Meeting)","fr":"MPNC (Réunion préalable - PM)"},
  {"id":"B02-20160301-047","en":"MPNDS (Pre-NDS Meeting)","fr":"MPPDN (Réunion préalable – PDN)"},
  {"id":"B02-20160301-049","en":"MPSNDS (Pre-SNDS Meeting)","fr":"MPSPDN (Réunion préalable – RPPDN)"},
  {"id":"B02-20160301-050","en":"NC (Notifiable Change)","fr":"NC (Préavis de modification)"},
  {"id":"B02-20160301-051","en":"NDS (New Drug Submission)","fr":"PDN (Présentation de drogue nouvelle)"},
  {"id":"B02-20210108-01","en":"NDS CV (New Drug Submission with flexibilities for Designated COVID-19 drug)","fr":"PDN CV (Présentation de drogue nouvelle avec flexibilités - Médicament COVID-19 désigné)"},
  {"id":"B02-20160301-068","en":"PBRER-C (Periodic Benefit Risk Evaluation Report - Confirmatory)","fr":"RPEAR-C (Rapport périodique d'évaluation des avantages et des risques - confirmation)"},
  {"id":"B02-20160301-069","en":"PBRER-PV (Periodic Benefit Risk Evaluation Report - Post-market Vigilance)","fr":"RPEAR-PV (rapport périodique d'évaluation des avantages et des risques - Vigilance après la mise en marché)"},
  {"id":"B02-20160301-075","en":"PRNDS (Priority Request NDS)","fr":"PRPDN (Demande de statut d’évaluation prioritaire - PDN)"},
  {"id":"B02-20160301-077","en":"PRSNDS (Priority Request SNDS)","fr":"PRSPDN (Demande de statut d’évaluation prioritaire - SPDN)"},
  {"id":"B02-20160301-078","en":"PSUR-C (Periodic Safety Update Report - Confirmatory)","fr":"RPPV-C (Rapport périodique de pharmacovigilance - Confirmation)"},
  {"id":"B02-20160301-079","en":"PSUR-PV (Periodic Safety Update Report - Post-market Vigilance)","fr":"RPPV-PV (Rapport périodique de pharmacovigilance -Vigilance après la mise en marché)"},
  {"id":"B02-20160301-080","en":"RMP-PV (Risk Management Plan - Post-market Vigilance)","fr":"PGR-PV (Plan de gestion des risques - Vigilance après la mise en marché)"},
  {"id":"B02-20160301-082","en":"SANDS (Supplement to an Abbreviated New Drug Submission)","fr":"SPADN (Supplément à une présentation abrégée de drogue nouvelle)"},
  {"id":"B02-20160301-084","en":"SNDS (Supplement to a New Drug Submission)","fr":"SPDN (Supplément à une présentation de drogue nouvelle)"},
  {"id":"B02-20160301-085","en":"SNDS-C (Supplement to a New Drug Submission - Confirmatory)","fr":"SPDN-C (Supplément à 'une présentation de drogue nouvelle - Confirmation)"},
  {"id":"B02-20160301-088","en":"UDRA (Undefined Regulatory Activity)","fr":"ARND (Activité réglementaire non définie)"},
  {"id":"B02-20160301-089","en":"YBPR (Yearly Biologic Product Report)","fr":"RAPB (Rapport annuel sur un produit biologique)"},
  {"id":"B02-20160301-018","en":"DINA (Application for Drug Identification Number)","fr":"DDIN (Demande d'identification numérique de drogue)"},
  {"id":"B02-20160301-019","en":"DINB (Application for Drug Identification Number - Biologic)","fr":"DIN-B (Demande d'identification numérique de drogue - produits biologiques)"},
  {"id":"B02-20160301-020","en":"DIND (Application for Drug Identification Number - Disinfectant Product)","fr":"DIN-D (Demande d'identification numérique de drogue - produits désinfectant)"},
  {"id":"B02-20160301-021","en":"DINF (Application for Drug Identification Number - Category IV Monograph Product)","fr":"DIN-F (Demande d'identification numérique de drogue - produit monographique de catégorie IV)"},
  {"id":"B02-20160301-022","en":"DINV (Application for Drug Identification Number - Veterinary)","fr":"DINV (Demande d'identification numérique de drogue - Vétérinaire)"},
  {"id":"B02-20160301-043","en":"MPDIN (Pre-Submission Meeting Information - DIN)","fr":"MPDIN (Réunions préalables - DIN)"},
  {"id":"B02-20160301-070","en":"PDC (Post-Authorization Division 1 Change)","fr":"CPA (Changement post-approbation de Titre 1)"},
  {"id":"B02-20160301-071","en":"PDCB (Post-Authorization Division 1 Change - Biologics)","fr":"CPA-B (Changement post-approbation de Titre 1 - biologiques)"},
  {"id":"B02-20190627-01","en":"IRSRPV (Issue Related Summary Report - Post-market Vigilance)","fr":"IRSR-PV (Rapport de synthèse relatif à un sujet de préoccupation)"},
  {"id":"B02-20190627-02","en":"PA-PV (Post-Authorization commitments - Post-market Vigilance)","fr":"PA-PV (Engagements postérieurs à l'autorisation - Vigilance après la commercialisation)"},
  {"id":"B02-20190627-03","en":"PSA-PV (Patient Safety/Advertising Ad-Hoc Post market requests - Post-market Vigilance)","fr":"PSA-PV (Demandes postérieures à la commercialisation sur la sécurité des patients/la publicité ad hoc)"},
  {"id":"B02-20190627-04","en":"RC-PV (Risk Communication - Post-market Vigilance)","fr":"RC-PV (Communication des risques - Vigilance après la commercialisation)"},
  {"id":"B02-20190627-05","en":"REG-PV (Post-Authorization Act and Regulations - Post-market Vigilance)","fr":"REG-PV (Loi et règlements postérieurs à l'autorisation - Vigilance après la commercialisation)"},
  {"id":"B02-20190627-06","en":"SANDS-C (Supplement to a New Abbreviated Drug Submission - Confirmatory","fr":"SPADN-C (Supplément à une présentation abrégée de drogue nouvelle - Confirmation)"},
  {"id":"B02-20160819-01","en":"Post-DIN Notification","fr":"Avis après la délivrance d'un DDIN"},
  {"id":"B02-20190627-07","en":"EUANDS (Extraordinary Use Abbreviated New Drug Submission)","fr":"PADN-UE (Présentation abrégée de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20190627-08","en":"EUSANDS (Extraordinary Use Supplement to a Abbreviated New Drug Submission)","fr":"SPADN-UE (Supplément à une présentation abrégée de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20160301-014","en":"CTA (Clinical Trial Application)","fr":"DEC (Demande d’essai clinique)"},
  {"id":"B02-20160301-015","en":"CTA-A (Clinical Trial Application - Amendment)","fr":"MDEC (Modification de demande d’essai clinique)"},
  {"id":"B02-20160301-072","en":"Pre-CTA (Pre-Clinical Trial Application)","fr":"Réunion préalable - DEC"},
  {"id":"B02-20160301-041","en":"MPANDS (Pre-Submission Meeting Information - ANDS)","fr":"MPPADN (Réunions préalables - ANDS)"},
  {"id":"B02-20160301-048","en":"MPSANDS (Pre-Submission Meeting Information - SANDS)","fr":"MPSPADN (Réunions préalables - SANDS)"},
  {"id":"B02-20180912-01","en":"RCC (Regulatory Cooperation Council)","fr":"RCC (Conseil de coopération en matière de réglementation)"},
  {"id":"B02-20200417-01","en":"COV19 (COVID-19 Interim Order Application)","fr":"COV19 (Demande d'ordonnance provisoire COVID-19)"},
  {"id":"B02-20200417-02","en":"COV19A (COVID-19 Interim Order Ap - Amendment)","fr":"COV19A (Demande d'ordonnance provisoire COVID-19 - Modification)"},
  {"id":"B02-20201028-01","en":"MPCOV (Pre-COVID-19 For IO Application Meeting)","fr":"MPCOV (Réunion préalable pour demande d'ordonnance provisoire COVID-19)"},
  {"id":"B02-20201214-01","en":"MPCOVA (Pre-COVID-19 For IO Application Amendment Meeting)","fr":"MPCOVA (Réunion préalable à une modification de demande d'ordonnance provisoire COVID-19)"},
  {"id":"B02-20160301-076","en":"PRORE (Protocol Review)","fr":"PRORE (Examens de protocole)"},
  {"id":"B02-20180522-01","en":"BE (Blood Establishment)","fr":"BE (Établissement de sang)"}

  ]